Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.55 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355639 | 1.00 | PREP (0.59) | PREPACE2HTR2CNPSR1PDK1 | |
| SCHEMBL15372095 | 1.00 | PREP (0.59) | PREPACE2HTR2CNPSR1PDK1 | |
| SCHEMBL25756732 | 0.96 | FKBP1A (0.56) | PREPACE2HTR2CPDK1PDK2 | |
| SCHEMBL14646671 | 0.96 | FKBP1A (0.56) | PREPACE2HTR2CPDK1PDK2 | |
| SCHEMBL29889013 | 0.94 | FKBP1A (0.55) | PREPACE2HTR2CPDK1PDK2 | |
| SCHEMBL14999594 | 0.94 | FKBP1A (0.55) | PREPACE2HTR2CPDK1PDK2 | |
| SCHEMBL28411733 | 0.91 | HTR2C (0.59) | PREPHTR2CPDK1PDK2PDK3 | |
| SCHEMBL25841627 | 0.91 | HTR2C (0.59) | PREPHTR2CPDK1PDK2PDK3 | |
| SCHEMBL16925462 | 0.91 | PREP (0.56) | PREPACE2HTR2CNPSR1PDK1 | |
| SCHEMBL16903405 | 0.88 | PREP (0.54) | PREPACE2HTR2CNPSR1PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746440-B1 | PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME | UNIV TEXAS (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-111655713-B | IAP inhibitor and application thereof in medicines | 广东东阳光药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116249697-A | Bicycloheptane pyrrolidine orexin receptor agonists | 默沙东有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| CN-108440507-B | Compound as apoptosis protein inhibitor and application thereof | 南京圣和药物研发有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-108440507-A | Compound as apoptosis protein inhibitor and its application | 南京圣和药业股份有限公司 | 2018-08-24 | — | — | CN | disclosed |
| US-20110287494-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVE | DAICEL CHEMICAL INDUSTRIES LTD (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110262977-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVE | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-1666459-B1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP (CA) | 2011-10-19 | — | — | EP | disclosed |
| EP-2330210-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVE | Daicel Chemical Industries, Ltd. (JP) | 2011-06-08 | — | — | EP | disclosed |
| EP-2330190-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVE | Daicel Chemical Industries, Ltd. (JP) | 2011-06-08 | — | — | EP | disclosed |
| US-7807426-B2 | Processes for producing optically active 1-substituted 2-methylpyrrolidine | KANEKA CORPORATION (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20070292926-A1 | Processes for Producing Optically Active 1-Substituted 2-Methylpyrrolidine and Intermediate Therefor | KANEKA CORPORATION (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1715054-A1 | PROCESSES FOR PRODUCING OPTICALLY ACTIVE 1-SUBSTITUTED 2-METHYLPYRROLIDINE AND INTERMEDIATE THEREFOR | KANEKA CORPORATION (JP) | 2006-10-25 | — | — | EP | disclosed |
| US-5550257-A | TREATING CENTRAL CHOLINERGIC DYSFUNCTION | AMERICAN CYANAMID COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110287494-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVE | IMPDH1, RNGTT, IMPDH2 | PREP 691/4885ACE2 2495/4885HTR2C 1878/4885 |
| US-20230142629-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | IRAK1, IRAK2, IRAK4 | PREP 1938/4885ACE2 2474/4885HTR2C 3834/4885 |
| US-20070292926-A1 | Processes for Producing Optically Active 1-Substituted 2-Methylpyrrolidine and Intermediate Therefor | FAR1, NOTUM, ALDH7A1 | PREP 1667/4885ACE2 2257/4885HTR2C 486/4885 |
| US-20110262977-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVE | PADI4, INMT, SMS | PREP 2416/4885ACE2 2356/4885HTR2C 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.